Key Takeaways
AtaiBeckley Inc. (NASDAQ:ATAI) will launch a pivotal Phase 3 study for its lead depression candidate in the second quarter of 2026, a key step forward supported by a cash runway the company projects will last into 2029. The clinical-stage biotechnology company is developing novel treatments for mental health conditions.
“Our $209.9 million in cash is expected to provide a runway through our anticipated Phase 3 topline readouts for BPL-003, as we advance toward the late-stage execution phase,” Srinivas Rao, Co-Founder and Chief Executive Officer of AtaiBeckley, said in a statement. He added that the company's capital position and pipeline breadth create a strong foundation for building shareholder value.
The company confirmed its Phase 3 ReConnection program for BPL-003, a nasal spray of mebufotenin benzoate for treatment-resistant depression (TRD), will proceed this quarter after a meeting with the US Food and Drug Administration. For the first quarter ended March 31, AtaiBeckley reported a net loss of $29.8 million, or $0.08 per share, compared to a net loss of $26.4 million, or $0.15 per share, for the same period last year.
The update follows a quarter where research and development expenses grew to $17.4 million from $11.3 million a year earlier, driven by clinical costs for BPL-003 and other pipeline candidates. The company’s cash and short-term securities stood at $209.9 million, which it expects to fund operations through key clinical milestones.
AtaiBeckley’s Phase 3 program for BPL-003 will consist of two studies, ReConnection-1 and ReConnection-2, evaluating the change from baseline in depression scores at week four as the primary endpoint. Both studies will also feature a 52-week open-label extension to gather long-term data.
Beyond its lead program, the company is advancing several other candidates. Topline results for VLS-01, a dimethyltryptamine (DMT) buccal film also being studied for TRD, are expected in the fourth quarter of 2026 from the Phase 2 Elumina trial. Additionally, initial data from a study evaluating a two-dose induction of BPL-003 combined with common antidepressants is anticipated in the same quarter. The company also noted positive Phase 2a results for EMP-01, an oral R-MDMA candidate for social anxiety disorder.
The year-over-year increase in operating expenses reflects higher clinical development costs and personnel-related expenses following the company’s combination with Beckley Psytech in November 2025.
The initiation of the Phase 3 trial marks a significant step for AtaiBeckley, moving its lead asset into the final and most expensive stage of clinical development before seeking regulatory approval. Investors will be watching for topline results from the VLS-01 and BPL-003 Part 4 studies expected in the fourth quarter of 2026.
This article is for informational purposes only and does not constitute investment advice.
